Oral Adjunctive therapy for anaphylactic reactions, Allergic conjunctivitis, Allergic reactions to blood or plasma, Angioedema, Perennial allergic rhinitis, Seasonal allergic rhinitis, Urticaria, Vasomotor rhinitis
Adult: 2 mg 4-6 hourly. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines). Child: 2-5 years 0.5 mg 4-6 hourly; 6-12 years 1 mg 4-6 hourly; >12 years Same as adult dose. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
What are the brands available for Dexchlorpheniramine in Malaysia?
Dexchlorpheniramine May be taken with or without food.
Contraindications
Treatment of lower respiratory tract symptoms (including asthma). Newborns or premature infants. Lactation. Concomitant use with MAOIs. Contraindications may vary between individual products (refer to specific product labelling for detailed information).
Special Precautions
Patient with history of bronchial asthma; CV disease (e.g. hypertension, ischaemic heart disease), narrow-angle glaucoma, prostatic hyperplasia, urinary obstruction (e.g. bladder neck obstruction), pyloroduodenal obstruction (e.g. stenosing peptic ulcer), thyroid dysfunction. Children and elderly. Pregnancy.
Adverse Reactions
Significant: CNS depression. Blood and lymphatic system disorders: Thrombocytopenia, agranulocytosis, haemolytic anaemia. Ear and labyrinth disorders: Vertigo, tinnitus, acute labyrinthitis. Eye disorders: Blurred vision, diplopia. Gastrointestinal disorders: Nausea, vomiting, constipation, diarrhoea, epigastric distress, xerostomia. General disorders and administration site conditions: Chills, fatigue. Immune system disorders: Anaphylactic shock. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Dizziness, ataxia, neuritis, paraesthesia, tremor. Psychiatric disorders: Hysteria, confusion, euphoria, excitement, insomnia, irritability, nervousness. Renal and urinary disorders: Urinary frequency, urinary retention. Skin and subcutaneous tissue disorders: Rash, urticaria, diaphoresis, photosensitivity.
This drug may cause CNS depression, if affected, do not drive or operate machinery.
Overdosage
Symptoms: CNS stimulation or depression; severe drowsiness, unsteadiness, hallucinations, seizures, respiratory depression; atropine-like signs and symptoms (e.g. dry mouth; fixed, dilated pupils; flushing, gastrointestinal symptoms). Management: Symptomatic and supportive treatment. Induce vomiting if vomiting has not occurred spontaneously. Perform aspiration or lavage to empty the stomach. Administer vasopressors to treat hypotension.
Drug Interactions
Prolonged and enhanced anticholinergic effects with MAOIs. Enhanced sedative effect with barbiturates, hypnotics, narcotic analgesics, sedatives and tranquilisers. May result in additive antimuscarinic activity with TCAs. May decrease therapeutic efficacy of oral anticoagulants.
Food Interaction
Enhanced sedative effect with alcohol.
Action
Description: Mechanism of Action: Dexchlorpheniramine, an alkylamine derivative, is the dextrorotatory isomer of chlorpheniramine and is approx twice as active as the racemic compound. It competes with histamine for H1 receptor sites on the effector cells, therefore inhibiting the responses caused by histamines. Pharmacokinetics: Absorption: Time to peak plasma concentration: Approx 3 hours. Metabolism: Metabolised in the liver. Excretion: Via urine. Elimination half-life: 20-30 hours.
Chemical Structure
Dexchlorpheniramine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 33036, Dexchlorpheniramine. https://pubchem.ncbi.nlm.nih.gov/compound/Dexchlorpheniramine. Accessed June 25, 2024.
R06AB02 - dexchlorpheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
References
Anon. Chlorphenamine Maleate, Dexchlorpheniramine Maleate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/05/2024.Anprodex Tablets 2 mg (Malaysian Pharmaceutical Industries Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 11/06/2024.Axcel Dexchlorpheniramine Tablets (Kotra Pharma [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 02/05/2024.Bayer New Zealand Limited. Polaramine Tablets, Film-coated and Syrup data sheet 17 February 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 02/05/2024.Buckingham R (ed). Chlorphenamine Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/05/2024.Dexchlormine Tablet (Dynapharm [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 11/06/2024.Dexchlorpheniramine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 11/06/2024.Dexchlorpheniramine. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 02/05/2024.Prime’s Dexchloramine Syrup 2 mg/5 mL (Prime Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 20/05/2024.Ryclora Liquid (Carwin Pharmaceutical Associates, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 02/05/2024.
Sign Out
Continue with Google